← Leaderboards
Oliver W. Press
Fred Hutchinson Cancer Research Center
$23,607,906
Attributed
$24,263,550
Total exposure
24
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$48,045,099 · 25
By mechanism
P01$31,482,989 · 7
R01$13,690,835 · 7
T32$1,155,645 · 1
P51$1,074,194 · 7
R21$580,828 · 1
M01$60,608 · 2
Top collaborators
- Claude F. Meares4 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- John M. Pagel$5,647,981
- Brenda Marie Sandmaier$22,185,663
Others in their field
Top investigators on “Radiolabeled”
- Steven H Liang · Emory University$25,718,454
- Robert H Mach · Wake Forest University$24,553,580
- Michael Rod Zalutsky · Duke University$16,391,432
- Robert M Glickman · New York University School Of Medicine$15,401,672
- Steven Grant Deeks · University Of California Los Angeles$13,965,041
- Louis J. Picker · Oregon Health And Science University$13,965,041
Research focus
RadiolabeledRadiotracerRadioimmunotherapyMonoclonal AntibodiesToxic EffectAntibodiesChimeric ProteinsOrganStreptavidinRadiationBiodistributionDoseRadioisotopesBiotinTumorDota-BiotinLymphomaRelapsePtprc GeneLabelPre-ClinicalMalignant NeoplasmsDrug KineticsRadioactivity
Grant awards (94)
Core C: Pharmaceutical Production$395,784
P01 · FY2019 · HL · contact PI
Core C: Pharmaceutical Production$398,666
P01 · FY2018 · HL · contact PI
Core C: Pharmaceutical Production$401,608
P01 · FY2017 · HL · contact PI
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION$592,471
T32 · FY2016 · CA · contact PI
Core C: Pharmaceutical Production$404,727
P01 · FY2016 · HL · contact PI
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION$563,174
T32 · FY2015 · CA · contact PI
Administrative and Statistical Core$450,309
P01 · FY2015 · CA · contact PI
Core C: Pharmaceutical Production$440,680
P01 · FY2015 · HL · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$386,431
R01 · FY2015 · CA · contact PI
Pretargeted Radioimmunotherapy for Hematologic Malignancies$317,115
P01 · FY2015 · CA · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$2,148,164
P01 · FY2014 · CA · contact PI
Administrative and Statistical Core$460,927
P01 · FY2014 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$405,431
R01 · FY2014 · CA · contact PI
CD38 Pretargeted Radioimmunotherapy for Myeloma$345,117
R01 · FY2014 · CA · contact PI
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot$343,617
R01 · FY2014 · CA · contact PI
Pretargeted Radioimmunotherapy for Hematologic Malignancies$304,825
P01 · FY2014 · CA · contact PI
Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot$64,750
R01 · FY2014 · CA · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$2,089,499
P01 · FY2013 · CA · contact PI
Administrative and Statistical Core$425,610
P01 · FY2013 · CA · contact PI
CD38 Pretargeted Radioimmunotherapy for Myeloma$334,444
R01 · FY2013 · CA · contact PI
Pretargeted Radioimmunotherapy for Hematologic Malignancies$301,631
P01 · FY2013 · CA · contact PI
Bispecific Antibody Engineering for AML RIT$298,976
R01 · FY2013 · CA · contact PI
CD45 Pretargeted Radioimmunotherapy for AML$275,448
R01 · FY2013 · CA · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$2,254,252
P01 · FY2012 · CA · contact PI
Administrative and Statistical Core$454,046
P01 · FY2012 · CA · contact PI
CD38 Pretargeted Radioimmunotherapy for Myeloma$355,791
R01 · FY2012 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$353,533
R01 · FY2012 · CA · contact PI
Pretargeted Radioimmunotherapy for Hematologic Malignancies$322,824
P01 · FY2012 · CA · contact PI
Bispecific Antibody Engineering for AML RIT$319,012
R01 · FY2012 · CA · contact PI
CD45 Pretargeted Radioimmunotherapy for AML$293,447
R01 · FY2012 · CA · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$2,115,352
P01 · FY2011 · CA · contact PI
Administrative and Statistical Core$455,374
P01 · FY2011 · CA · contact PI
CD38 Pretargeted Radioimmunotherapy for Myeloma$374,608
R01 · FY2011 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$353,533
R01 · FY2011 · CA · contact PI
Pretargeted Radioimmunotherapy for Hematologic Malignancies$324,833
P01 · FY2011 · CA · contact PI
Bispecific Antibody Engineering for AML RIT$318,897
R01 · FY2011 · CA · contact PI
CD45 Pretargeted Radioimmunotherapy for AML$293,851
R01 · FY2011 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$364,467
R01 · FY2010 · CA · contact PI
Bispecific Antibody Engineering for AML RIT$328,617
R01 · FY2010 · CA · contact PI
CD45 Pretargeted Radioimmunotherapy for AML$303,343
R01 · FY2010 · CA · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$250,000
P01 · FY2010 · CA · contact PI
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES$155,086
P51 · FY2010 · RR · contact PI
PRETARGETED ANTI-CD45 RADIOIMMUNOTHERAPY STUDIES IN MACAQUES$155,086
P51 · FY2010 · RR · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$2,026,942
P01 · FY2009 · CA · contact PI
Improved Targeting Strategies$450,632
P01 · FY2009 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$364,467
R01 · FY2009 · CA · contact PI
Bispecific Antibody Engineering for AML RIT$344,762
R01 · FY2009 · CA · contact PI
CD45 Pretargeted Radioimmunotherapy for AML$318,935
R01 · FY2009 · CA · contact PI
PRETARGETED ANTI-CD45 RADIOIMMUNOTHERAPY STUDIES IN MACAQUES$315,187
P51 · FY2009 · RR · contact PI
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES$157,595
P51 · FY2009 · RR · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$1,944,619
P01 · FY2008 · CA · contact PI
Improved Targeting Strategies$440,200
P01 · FY2008 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$380,807
R01 · FY2008 · CA · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$1,865,350
P01 · FY2007 · CA · contact PI
Improved Targeting Strategies$379,337
P01 · FY2007 · CA · contact PI
CD45 Pretargeted Radioimmunotherapy for AML$292,688
R01 · FY2007 · CA · contact PI
Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma$286,141
R21 · FY2007 · CA · contact PI
PHASE I SAFETY/FEASIBILITY: GENETICALLY MODIFIED AUTOLOGOUS T CELLS IN LYMPHOMA$3,500
M01 · FY2007 · RR · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$1,874,598
P01 · FY2006 · CA · contact PI
PRETARGETING RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS$335,205
R01 · FY2006 · CA · contact PI
CD45 Pretargeted Radioimmunotherapy for AML$295,228
R01 · FY2006 · CA · contact PI
Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma$294,687
R21 · FY2006 · CA · contact PI
Improved Targeting Strategies$199,103
P01 · FY2006 · CA · contact PI
PRETARGETED ANTI-CD45 RADIOIMMUNOTHEARPY STUDIES IN MACAQUES$94,326
P51 · FY2006 · RR · contact PI
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES$94,326
P51 · FY2006 · RR · contact PI
PHASE I USING AUTOLOGOUS CD20-SPECIFIC CD8+ T CELL CLONES IN LYMPHOMAS$14,886
M01 · FY2006 · RR · contact PI
Therapy of Lymphoma/Leukemia with Monoclonal Antibodies$1,942,544
P01 · FY2005 · CA
CD45 Pretargeted Radioimmunotherapy for AML$345,360
R01 · FY2005 · CA
PRETARGETING RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS$343,272
R01 · FY2005 · CA
Improved Targeting Strategies$196,033
P01 · FY2005 · CA
Administrative Core$177,176
P01 · FY2005 · CA
RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ABSORPTION THERAPY STUDIES IN MACAQUES$102,588
P51 · FY2005 · RR
PHASE I USING AUTOLOGOUS CD20-SPECIFIC CD8+ T CELL CLONES IN LYMPHOMAS$31,379
M01 · FY2005 · RR
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES$1,798,520
P01 · FY2004 · CA
CD45 Pretargeted Radioimmunotherapy for AML$504,933
R01 · FY2004 · CA
PRETARGETING RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS$343,272
R01 · FY2004 · CA
Phase I using autologous CD20-specific CD8+ T cell clones in lymphomas$10,843
M01 · FY2004 · RR
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES$1,756,343
P01 · FY2003 · CA
Chimeric Anti CD20 T Cell Receptors for Lymphoma Therapy$447,750
R01 · FY2003 · CA
PRETARGETING RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS$343,272
R01 · FY2003 · CA
INTRACELLULAR TRAFFICKING OF IMMUNOTOXINS$289,214
R01 · FY2003 · CA
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES$1,715,366
P01 · FY2002 · CA
Chimeric Anti CD20 T Cell Receptors for Lymphoma Therapy$427,470
R01 · FY2002 · CA
PRETARGETING RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS$359,514
R01 · FY2002 · CA
INTRACELLULAR TRAFFICKING OF IMMUNOTOXINS$276,623
R01 · FY2002 · CA
RADIOLABELLED ANTIBODY THERAPY OF B CELL LYMPHOMA$0
P01 · FY2002 · CA
Chimeric Anti CD20 T Cell Receptors for Lymphoma Therapy$461,767
R01 · FY2001 · CA
PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS$330,875
R01 · FY2001 · CA
INTRACELLULAR TRAFFICKING OF IMMUNOTOXINS$243,482
R01 · FY2001 · CA
RADIOLABELLED ANTIBODY THERAPY OF B CELL LYMPHOMA$0
P01 · FY2001 · CA
RADIOLABELLED ANTIBODY THERAPY OF B CELL LYMPHOMA$0
P01 · FY2001 · CA
PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS$274,706
R01 · FY2000 · CA
INTRACELLULAR TRAFFICKING OF IMMUNOTOXINS$253,920
R01 · FY2000 · CA
RADIOLABELLED ANTIBODY THERAPY OF B CELL LYMPHOMA$0
P01 · FY2000 · CA